Both are baits for investors. Remember that within 3 weeks and around 2 months after CEO had done selling stock($8.8m), Fusilev's guidance was dropped from 200m/year to 90m/year
Apaz has FAILED BOTH PHASE 3 STUDIES. Allergan the partner gave away ALL RIGHTS to this drug for a TINY $15M investment that was required. If Apaz had any chance(even 20%) of approval, wouldn't allergan have kept those rights ?
Wonder when this B.S will stop
You have heard from others why Apaz didn’t make business sense for Allergan, I would just add the Q what type of dumb Allergan management would want a cancer drug in their portfolio when they didn’t have any cancer drugs to begin with? Look at their Yahoo profile and their web site I’m pasting below. They prolly figured out that the current sales team is inadequate to sell it and they would need to create a new sales force. Don’t know Allergan’s management history but I wouldn’t be surprised if management who made the deal all got let go. What stupidity in getting rights to Apaz. SPPI made nice bucks on this deal, Raj should be commended for getting all that cash from them.
Yahoo profile - “The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and over-the-counter skin care products; and urologics products. The Medical Devices segment offers …. “
A look at their web sites describes their urological products as follows “… overactive bladder (OAB) and other urological and genitourinary disorders. Allergan currently has two products in this portfolio: SANCTURA XR®, a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency and urinary frequency approved in 2007 by the U.S. Food and Drug Administration (FDA) and BOTOX”
Not a question of what fits
If apaz was not worth a tiny 15m which some of u state could be worth 100s of m would they have given back their rights so easily for a tiny fraction. Don't believe in anything cmpny says. They say under safe harbor of forward looking stmt. Very easily they will retract like they did shamelessly within 3 weeks for fusilev
Apaziquone didnt fit Allergan business. Allergan did a smart deal, they are not operating in the Urologi business. Thats why. And they didnt want any more R&D costs on Apaziquone. But they didnt gave it away.
Spectrum will have to pay royalty on sales to Allergan... Så Allergan definetly still have a stake in Apaziquone.
The reason they have $90 MM for 2013 is that Q1 was $11.8 M and Q2 will likely be the same and Q3 will be impacted as well. Even assuming a full Q3, $90M less $23.6M for 1H2013 is $66.4M or a $133MM Annual Run Rate not $90 MM. Please be accurate.
Why do you keep posting on this board if you dont like the company and dont own the stock. There is only 2 reasons you are short in the stock or you work for the shorts, either way you are pathetic there is so many losers like you on all forums and they are so obvious 1 week they bash the stock so they can buy or cover cheap and next week they pump the stock so they can sell or short high.
Might work on some of the small investors but do you really think you are gonna scare the big guys come on get a real job.
I own this stock do you see me trying to pump the stock every day? No thats because I know that it has no real effect, so PLEASE spare us from all your nonsense im tired of all this spam.
Sentiment: Strong Buy
Imho, you are betting against the odds. That is fair but if the information Keller is sharing on Apaz are true, and I have no reason to believe that they are not, there is a reasonable chance that Apaz may be on the market in 2014/15. Also I like Belinostat and the off label potential alongside the G-CSF opportunity. All have a chance to see the market. It is no doubt a long way until FDA approval and Sales execution but the new team I trust. Only time will show who is right but again it is you betting against the odds. I can not wish you good luck with it, because I am long.
Sentiment: Strong Buy
Once again, you continue to mislead:
ONLY 2013 guidance for Fusilev is$80 to $90 million as the wholeseller overstuffing completely understates Fusilev's annual run rate for Q1, Q2 and into Q3. To state otherwise is intentionally misleading.
Accordingly, Q1 only had $11.8 m of Fusilev revenues which will continue into Q3. In no way is it accurate to say Fulilev's annual run rate will be $90 MM. That is purely a 2013 calendar year issue which is a "one off".
Let's see what Q4 provides.
The wholeseller thing doesn't just cause undersized revenues for early 2013, but possibly created oversided revenues for part of 2012. So when you model a return to normal, you have to first go figure out what normal is.
when you say it is purely a 2013 issue you are misleading. Are you saying for some reason generic leucovorin will again go on shortage ? Are you saying the long term contracts that sagent has been aggressively procuring will vanish in thin air after 2013 ? Are you saying no new generic leucovorin players will enter the market ? Are you saying obamacare will not have any impact on coverage of fusilev...are you saying the new Bill cassidy bill pending in congress will not be passed and the generic leucovorin players will continue to sell at uneconomical prices ?
the reason for $90m guidance is they think clinics will continue to buy , because clearly keller mentioned that docs are also small business owners and they get 6% discount of higher price. But we dont know whats going to happen when obamacare comes in.